OrbiMed Asia Partners (OAP) has made an additional investment of $7.5m in Indian pharmaceutical company Vivimed Labs.
The US-based private equity firm previously invested $42.5m in the same company in September 2017.
Go deeper with GlobalData
Vivimed Labs plans to use the funds to expand its business.
US-based biopharmaceutical company Kadmon Holdings plans to raise $40m through a public offering of shares.
The company plans to use the proceeds for the clinical development of its pipeline products and for general corporate purposes.
ANI Pharmaceuticals has acquired the new drug applications (NDAs), as well as the US marketing rights for four drugs developed by biopharmaceutical company AstraZeneca Plc for $46.5m.
The four drugs, including ATACAND, ATACAND HCT, ARIMIDEX and CASODEX, will continue to be marketed by AstraZeneca outside the US.
The acquisition will help the specialist pharmaceutical company to diversify its commercial portfolio.
Both companies involved in the transaction are based in the UK.
Tasly Pharmaceutical Group plans to raise CNY2bn ($305.84m) through the private placement of medium-term notes.
The Chinese pharmaceutical company plans to use the funds to repay bank loans and to fulfil its medium and long-term capital needs.
Chinese biotechnology company Sansure Biotech has raised $77m in a strategic financing round led by Lilly Asia Ventures.
